Halberd (HALB) 10-Q 29 Aug 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Apr. 30, 2022	Aug. 16, 2022
Cover [Abstract]
Entity Registrant Name	HALBERD CORPORATION
Entity Central Index Key	0001458631
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Apr. 30, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		515,874,842
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-8731
Entity Incorporation State Country Code	CO
Entity Tax Identification Number	87-3538414
Entity Interactive Data Current	Yes
Entity Address Address Line 1	P.O. Box 25
Entity Address City Or Town	Jackson Center
Entity Address State Or Province	PA
Entity Address Postal Zip Code	16133
City Area Code	814
Local Phone Number	786-8849
Security 12b Title	Common
Trading Symbol	HALB

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Current Assets:
Cash	$ 8,162	$ 40,321
Prepaid expense	5,410	21,750
Total current assets	13,572	62,071
Fixed assets, net	4,819	1,281
Total Assets	18,391	63,352
Current Liabilities:
Accounts payable	267,813	177,010
Accrued expenses	9,717	5,300
Convertible judgments payable	206,934	216,400
Total current liabilities	484,464	398,710
Long term liabilities:
Note payable, SBA loan	150,000	150,000
Total liabilities	634,464	548,710
Commitments and contingencies	0	0
Stockholders' equity (deficit):
Preferred stock, $0.0001 par value, 25,000,000 shares authorized, 10,000,000 shares issued and outstanding	1,000	1,000
Common stock, $0.0001 par value, 800,000,000 shares authorized, 513,650,338 and 511,621,968 shares issued and outstanding at April 30, 2022 and July 31, 2021, respectively	51,365	51,162
Additional paid in capital	5,516,115	4,282,530
Accumulated deficit	(6,184,553)	(4,820,050)
Total stockholders' equity (deficit)	(616,073)	(485,358)
Total liabilities and stockholders' equity (deficit)	$ 18,391	$ 63,352

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Apr. 30, 2022	Jul. 31, 2021
Statement Of Financial Position Abstract
Common stock, shares par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares issued	513,650,338	511,621,968
Common stock, shares outstanding	513,650,338	511,621,968
Preferred stock, shares par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	10,000,000	10,000,000
Preferred stock, shares outstanding	10,000,000	10,000,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Revenue	$ 1,217	$ 1,144	$ 5,883	$ 4,182
Cost of revenues	0	2,068	214	2,068
Gross Profit	1,217	(924)	5,669	2,114
Operating Expenses:
General and administrative	20,934	22,146	79,302	74,576
Research and development	203,408	199,664	710,788	471,446
Professional fees	72,509	5,500	575,541	52,948
Total operating expenses	296,851	227,310	1,365,631	598,970
Operating loss	(295,634)	(228,234)	(1,359,962)	(596,856)
Other income (expense):
Interest expense	(1,538)	(1,400)	(4,541)	(18,939)
Total other income (expense)	(1,538)	(1,400)	(4,541)	(18,939)
Net loss	$ (297,172)	$ (229,634)	$ (1,364,503)	$ (615,795)
Weighted average common shares outstanding - basic	512,867,867	366,469,029	512,028,140	432,475,901
Weighted average common shares outstanding - fully diluted	512,867,867	366,469,029	512,028,140	432,475,901
Net loss per common share - basic	$ 0	$ 0	$ 0	$ 0
Net loss per common share - fully diluted	$ 0	$ 0	$ 0	$ 0

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)	Total	Accumulated Deficit	Common Stock	Preferred Stock	Additional Paid-In Capital
Balance, shares at Jul. 31, 2020			302,721,539	10,000,000
Balance, amount at Jul. 31, 2020	$ (292,776)	$ (3,859,276)	$ 30,272	$ 1,000	$ 3,535,228
Common stock issued for the exercise of warrants, shares			1,000,000
Common stock issued for the exercise of warrants, amount	10,000	0	$ 100	0	9,900
Common stock issued for settlement of 3(a)(10) debts, shares			167,900,429
Common stock issued for settlement of 3(a)(10) debts, amount	58,765	0	$ 16,790	0	41,975
Warrants granted for services	20,612	0	0	0	20,612
Contributed capital	482,316	0	0	0	482,316
Net loss	(615,795)	(615,795)	$ 0	$ 0	0
Contributed capital	482,315
Balance, shares at Apr. 30, 2021			471,621,968	10,000,000
Balance, amount at Apr. 30, 2021	(336,878)	(4,475,071)	$ 47,162	$ 1,000	4,090,031
Balance, shares at Jan. 31, 2021			419,621,968	10,000,000
Balance, amount at Jan. 31, 2021	(342,944)	(4,245,437)	$ 41,962	$ 1,000	3,859,531
Common stock issued for settlement of 3(a)(10) debts, shares			52,000,000
Common stock issued for settlement of 3(a)(10) debts, amount	18,200	0	$ 5,200	0	13,000
Net loss	(229,634)	(229,634)	0	0	0
Contributed capital	217,500	0	$ 0	$ 0	217,500
Balance, shares at Apr. 30, 2021			471,621,968	10,000,000
Balance, amount at Apr. 30, 2021	(336,878)	(4,475,071)	$ 47,162	$ 1,000	4,090,031
Balance, shares at Jul. 31, 2021			511,621,968	10,000,000
Balance, amount at Jul. 31, 2021	(485,358)	(4,820,050)	$ 51,162	$ 1,000	4,282,530
Common stock issued for settlement of 3(a)(10) debts, shares			27,044,110
Common stock issued for settlement of 3(a)(10) debts, amount	9,466	0	$ 2,704	0	6,762
Warrants granted for services	479,322	0	0	0	479,322
Net loss	(1,364,503)	(1,364,503)	0	0	0
Contributed capital	745,000	0	$ 0	0	745,000
Shares cancelled, shares			(25,015,740)
Shares cancelled, amount	0	0	$ (2,501)	$ 0	2,501
Balance, shares at Apr. 30, 2022			513,650,338	10,000,000
Balance, amount at Apr. 30, 2022	(616,073)	(6,184,553)	$ 51,365	$ 1,000	5,516,115
Balance, shares at Jan. 31, 2022			511,621,968	10,000,000
Balance, amount at Jan. 31, 2022	(624,019)	(5,887,381)	$ 51,162	$ 1,000	5,211,200
Common stock issued for settlement of 3(a)(10) debts, shares			27,044,110
Common stock issued for settlement of 3(a)(10) debts, amount	9,466	0	$ 2,704	0	6,762
Warrants granted for services	28,152	0	0	0	28,152
Net loss	(297,172)	(297,172)	0	0	0
Contributed capital	267,500	0	$ 0	0	267,500
Shares cancelled, shares			(25,015,740)
Shares cancelled, amount	0	0	$ (2,501)	$ 0	2,501
Balance, shares at Apr. 30, 2022			513,650,338	10,000,000
Balance, amount at Apr. 30, 2022	$ (616,073)	$ (6,184,553)	$ 51,365	$ 1,000	$ 5,516,115

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (1,364,503)	$ (615,795)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	315	0
Common stock warrants issued for services	479,322	20,612
Decrease (increase) in prepaid assets	16,340	(14,583)
Increase (decrease) accounts payable	90,803	69,529
Increase (decrease) accrued expenses	4,417	3,839
Net cash used in operating activities	(773,306)	(536,398)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets	(3,853)	0
Net used in investing activities	(3,853)	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds received from exercise of warrants	0	10,000
Proceeds received on capital contributions	745,000	482,315
Proceeds received from note payable, SBA loan	0	150,000
Net cash provided by financing activities	745,000	642,315
NET CHANGE IN CASH	(32,159)	105,917
CASH AT BEGINNING OF PERIOD	40,321	2,086
CASH AT END OF PERIOD	8,162	108,003
SUPPLEMENTAL INFORMATION:
Interest paid	124	15,100
Income taxes paid	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of common stock issued on settlement of 3(a)(10) debts	$ 649,059	$ 6,904,338

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Apr. 30, 2022
Basis of Presentation and Significant Accounting Policies
Basis of Presentation and Significant Accounting Policies	Note 1 – Basis of Presentation and Significant Accounting Policies Nature of Business Halberd Corporation (“Halberd”, “We”, “Us”, “the Company”) was formed in the State of Nevada on January 26, 2009. It changed its name to Tykhe Corporation on April 22, 2014, and then redomiciled to Colorado and changed its name to Alaric Corporation on January 25, 2017. On March 22, 2020, it changed its name to HALB Transition Corporation, before completing a reorganization whereby the name of the public company again became Halberd Corporation, and Alaric Corporation then became its wholly-owned subsidiary. The merger was accounted for as a reverse purchase acquisition in accordance with the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) 805-50, whereby the financial statements of the Target company (Halberd Corporation) were treated as the acquiring company, and the equity section of the balance sheet and earnings per share of Halberd Corporation were retroactively restated to reflect the effect of the 1:1 exchange ratio of the equity of Alaric Corporation exchanged for the equity of Halberd Corporation. There were no assets or liabilities of either entity prior to the business combination, therefore there was no Goodwill or gain or loss on the business combination. Halberd’s primary business is the pursuit of treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc. Basis of Accounting Our financial statements are prepared using the accrual method of accounting as generally accepted in the United States of America (U.S. GAAP) and the rules of the Securities and Exchange Commission (SEC). Basis of Presentation The accompanying financial statements include the accounts of the following entities, all of which are under common control and ownership as of the date of this report: Name of Entity Form of Entity State of Incorporation Relationship Halberd Corporation Corporation Colorado Parent Alaric Corporation Corporation Colorado Subsidiary All significant inter-company transactions have been eliminated in the preparation of these financial statements. These statements reflect all adjustments, which in the opinion of management, are necessary for fair presentation of the information contained therein. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. It is suggested that these unaudited financial statements be read in conjunction with the financial statements of the Company for the year ended July 31, 2021 and notes thereto included in the Company's annual report. The Company has adopted a fiscal year end of July 31 st Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Segment Reporting FASB ASC 280-10-50 requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. All of the Company’s stores are considered operating segments, and will be aggregated into one reportable segment given the similarities in economic characteristics among the operations represented by the stores and the common nature of the products, customers and methods of distribution. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts payable and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company had a convertible note payable that required fair value measurement on a recurring basis. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under Topic 606, revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We determine revenue recognition through the following steps: ● identification of the contract, or contracts, with a customer; ● identification of the performance obligations in the contract; ● determination of the transaction price; ● allocation of the transaction price to the performance obligations in the contract; and ● recognition of revenue when, or as, we satisfy a performance obligation. The Company’s revenues currently consist of the sale of CBD products, including patches, roll-on applications, sprays and ointments. These products are primarily sold direct-to-consumers online, and occasionally directly to local pharmacies. Sales are recorded when the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured, which is typically when products are shipped. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not been completed. Cost of Merchandise Sales and Occupancy Costs Cost of merchandise sales and occupancy costs includes the following types of expenses: purchase price of inventory sold, including inbound freight charges; shipping and handling costs; inventory shrinkage costs and valuation adjustments; payroll and benefits costs; store occupancy costs, including rent, common area maintenance, property taxes, utilities, insurance, and depreciation of leasehold improvements and capitalized lease assets. Also included in cost of merchandise sales and occupancy costs is certain consideration received from vendors for vendor rebates, allowances and discounts. Advertising and Promotion All costs associated with advertising and promoting products are expensed as incurred. These expenses approximated $53,936 and $46,624 for the nine months ended April 30, 2022 and 2021, respectively, as presented in general and administrative expenses within the consolidated statements of operations. Research and Development Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not. Basic and Diluted Loss per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty's performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	9 Months Ended
	Apr. 30, 2022
Going Concern
Going Concern	Note 2 – Going Concern As shown in the accompanying condensed consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of $6,184,553, negative working capital of $470,892, and as of April 30, 2022, the Company’s cash on hand may not be sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new customers to increase revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. Management believes these factors will contribute toward achieving profitability. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Convertible Judgments Payable a

Convertible Judgments Payable and Contingent Liabilities	9 Months Ended
	Apr. 30, 2022
Convertible Judgments Payable and Contingent Liabilities
Convertible Judgments Payable and Contingent Liabilities	Note 3 – Convertible Judgments Payable and Contingent Liabilities On May 7, 2014, the Company entered into a court ordered settlement in Securities Counselors, Inc. v. Halberd Corporation On November 25, 2014, in Securities Counselors, Inc. v. Texas Wyoming Drilling, Inc. Securities Counselors, Inc. v. Halberd Corporation That November 25, 2014, Securities Counselors, Inc. v. Texas Wyoming Drilling, Inc Securities Counselors, Inc. v. Texas Wyoming Drilling, Inc. Securities Counselors, Inc. v. Texas Wyoming Drilling, Inc As of April 30, 2022, there was a balance outstanding of $30,449 on this judgment that could be converted into approximately 86,998,604 shares of the Company’s common stock at a rate of approximately $0.00035 per share. A total of 234,944,539 shares were issued in satisfaction of approximately $82,231 of this obligation over various dates from August 5, 2020 through February 18, 2022. The Company has accounted for its judgment liability in accordance with ASC 450 - Contingencies

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Apr. 30, 2022
Fair Value of Financial Instruments
Fair Value of Financial Instruments	Note 4 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of April 30, 2022 and July 31, 2021, respectively: Fair Value Measurements at April 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 8,162 $ - $ - Total assets 8,162 - - Liabilities Convertible judgments payable - 6,582,399 - Note payable, SBA loan - 150,000 - Total liabilities - 6,732,399 - $ 8,162 $ (6,732,399 ) $ - Fair Value Measurements at July 31, 2021 Level 1 Level 2 Level 3 Assets Cash $ 40,321 $ - $ - Total assets 40,321 - - Liabilities Convertible judgments payable - 15,591,498 - Note payable, SBA loan - 150,000 - Total liabilities - 15,741,498 - $ 40,321 $ (15,741,498 ) $ - The fair value of our convertible judgments payable is based on the fair market value of the underlying shares that are to be used to settle the judgments, and are considered Level 3 inputs as defined by ASC Topic 820-10-35.The fair value is based on the exit price using the Company’s common stock at the balance sheet dates. The fair value is greater than the amounts presented on the balance sheets as follows: April 30, July 31, 2022 2021 Fair value of convertible judgments payable $ 6,582,399 $ 15,591,498 Historical value of convertible judgments payable on balance sheets 206,935 216,400 $ 6,375,464 $ 15,375,098 There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the nine months ended April 30, 2022 or the year ended July 31, 2021.

Note Payable, SBA Loan

Note Payable, SBA Loan	9 Months Ended
	Apr. 30, 2022
Note Payable, SBA Loan
Note Payable, SBA Loan	Note 5 – Note Payable, SBA Loan Note payable, SBA loan consisted of the following at April 30, 2022 and July 31, 2021, respectively: April 30, July 31, 2022 2021 On September 2, 2020, the Company, borrowed $150,000 from Standard Financing, pursuant to a Promissory Note issued by the Company to Standard Financing (the “SBA Loan”). The loan was made pursuant to the Covid-19 Economic Injury Disaster Loan Program established as part of the Coronavirus Aid, Relief, and Economic Security Act (the “EIDL Program”). The SBA Loan carried interest at 3.75% per annum, payable in $731 monthly payments over thirty (30) years from the date of the note, with the initial payment deferred until September 2, 2022. $ 150,000 $ 150,000 Total note payable, SBA loan $ 150,000 $ 150,000 The Company recorded interest expense on notes payable in the amount of $4,417 and $3,839 for the nine months ended April 30, 2022 and 2021, respectively.

Changes in Stockholders' Equity

Changes in Stockholders' Equity (Deficit)	9 Months Ended
	Apr. 30, 2022
Changes in Stockholders' Equity (Deficit)
Changes in Stockholders' Equity (Deficit)	Note 6 – Changes in Stockholders’ Equity (Deficit) Series A Preferred Stock The Company is authorized to issue 25,000,000 shares of preferred stock with a par value of $0.0001 per share, of which 10,000,000 have been designated as Series A Preferred Stock (“Series A Preferred”), with the remaining 15,000,000 shares available for designation from time to time by the Board as set forth below. As of April 30, 2022, there were 10,000,000 shares of Series A Preferred issued and outstanding. The Board of Directors is authorized to determine any number of series into which the undesignated shares of preferred stock may be divided and to determine the rights, preferences, privileges and restrictions granted to any series of the preferred stock. Common Stock Common stock consists of $0.0001 par value, 800,000,000 shares authorized, of which 513,650,338 shares were issued and outstanding as of April 30, 2022. Common Stock Issued in Satisfaction of Convertible Judgments Payable On February 18, 2022, the Company issued 27,044,110 shares in satisfaction of $9,466 of Judgments Payable at a conversion rate of $0.00035 per share pursuant to a court ordered judgment under Rule 3(a)(10). Cancellation of Common Stock On February 21, 2022, the Company cancelled 25,015,740 previously issued shares due to non-performance. Contributed Capital On various dates between August 1, 2021 and April 27, 2022, Epidemiologic Solutions Corp. contributed capital in the combined amount of $745,000 to pay expenses for operations, primarily for its research and development.

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Apr. 30, 2022
Common Stock Warrants
Common Stock Warrants	Note 7 – Common Stock Warrants Warrants to purchase a total of 485,850,000 shares of common stock at a weighted average strike price of $0.01 were outstanding as of April 30, 2022. Warrants Granted for Services On April 24, 2022, the Company issued warrants to purchase 1,000,000 shares, exercisable at $0.019 per share over a ten-year term, to an individual for services provided. The estimated fair value of the warrants using the Black-Scholes Pricing Model, based on a weighted average volatility rate of 239% and a weighted average call option value of $0.0188, was $18,768. On April 24, 2022, the Company issued warrants to purchase 500,000 shares, exercisable at $0.019 per share over a ten-year term, to an individual for services provided. The estimated fair value of the warrants using the Black-Scholes Pricing Model, based on a weighted average volatility rate of 239% and a weighted average call option value of $0.0188, was $9,384. On January 22, 2022, the Company issued warrants to purchase 750,000 shares, exercisable at $0.0196 per share over a ten-year term, to an individual for services provided. The estimated fair value of the warrants using the Black-Scholes Pricing Model, based on a weighted average volatility rate of 292% and a weighted average call option value of $0.0196, was $14,685. On January 15, 2022, the Company issued warrants to purchase 10,000,000 shares, exercisable at $0.0206 per share over a ten-year term, to an individual for services provided. The estimated fair value of the warrants using the Black-Scholes Pricing Model, based on a weighted average volatility rate of 293% and a weighted average call option value of $0.0206, was $205,788. On December 15, 2021, the Company issued warrants to purchase 1,000,000 shares, exercisable at $0.0175 per share over a ten-year term, to an individual for services provided. The estimated fair value of the warrants using the Black-Scholes Pricing Model, based on a weighted average volatility rate of 297% and a weighted average call option value of $0.0175, was $17,484. On December 5, 2021, the Company issued warrants to purchase 10,000,000 shares, exercisable at $0.0188 per share over a ten-year term, to an individual for services provided. The estimated fair value of the warrants using the Black-Scholes Pricing Model, based on a weighted average volatility rate of 300% and a weighted average call option value of $0.0188, was $187,853. On December 5, 2021, the Company issued warrants to purchase 1,000,000 shares, exercisable at $0.0188 per share over a ten-year term, to an individual for services provided. The estimated fair value of the warrants using the Black-Scholes Pricing Model, based on a weighted average volatility rate of 300% and a weighted average call option value of $0.0188, was $18,785. On December 5, 2021, the Company issued warrants to purchase 350,000 shares, exercisable at $0.0188 per share over a ten-year term, to an individual for services provided. The estimated fair value of the warrants using the Black-Scholes Pricing Model, based on a weighted average volatility rate of 300% and a weighted average call option value of $0.0188, was $6,575. Amended Warrants On December 5, 2021, the Company cancelled previously issued warrants to purchase 250,000 shares, exercisable at $0.0235 per share and issued new warrants to purchase 250,000 shares, exercisable at $0.0188 per share over a ten-year term, to an individual for services provided. The estimated fair value of the warrants using the Black-Scholes Pricing Model, based on a weighted average volatility rate of 300% and a weighted average call option value of $0.0188, was $4,696, which was not materially different than the value of the cancelled warrants.

Income Taxes

Income Taxes	9 Months Ended
	Apr. 30, 2022
Income Taxes
Income Taxes	Note 8 – Income Taxes The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax basis of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. As of April 30, 2022, the Company incurred a taxable net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. The Company had approximately $3,935,000 of federal net operating loss carry forwards at April 30, 2022. The net operating loss carry forwards, if not utilized, will begin to expire in 2029. The components of the Company’s deferred tax asset are as follows: April 30, July 31, 2022 2021 Deferred tax assets: Net operating loss carry forwards $ 826,350 $ 640,500 Net deferred tax assets before valuation allowance $ 826,350 $ 640,500 Less: Valuation allowance (826,350 ) (640,500 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of losses, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at April 30, 2022 and July 31, 2021, respectively. The Company had no uncertain tax positions as of April 30, 2022. A reconciliation between the amounts of income tax benefit determined by applying the applicable U.S. and State statutory income tax rate to pre-tax loss is as follows: April 30, July 31, 2022 2021 Federal and state statutory rate 21 % 21 % Change in valuation allowance on deferred tax assets (21%) (21%)

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Apr. 30, 2022
Commitments and Contingencies
Commitments and Contingencies	Note 9 – Commitments and Contingencies The Company may be involved in various inquiries, administrative proceedings and litigation relating to matters arising from our operations prior to the change in management and spin-off of our subsidiary on July 31, 2012. The Company is not currently a defendant in any material litigation and is not aware of any threatened litigation that could have a material effect on the Company. Management is not able to estimate the minimum loss to be incurred, if any, as a result of the final outcome of these matters but believes they are not likely to have a material adverse effect upon the Company’s financial position or results of operations and, accordingly, no provision for loss has been recorded. The Company performs research and development on its extracorporeal technological method of treating many disease states, including Alzheimer’s Disease, PTSD, Parkinson’s Disease, epilepsy and other neurodegenerative diseases, sepsis, meningitis and pandemics. These research and development activities are outsourced to Arizona State University (ASU) pursuant to an Industry Sponsored Research Agreement, which the Company and ASU entered into on September 1, 2020 (Research Agreement). The Research Agreement, which terminates on November 30, 2022, calls for monthly payments of $50,000, not to exceed $1,371,782. As of July 31, 2021, the Company has paid an aggregate $521,782, leaving $850,000 owed on the agreement. On May 7, 2014, the Company entered into a court ordered settlement for a total of $279,447 that is to be settled with the payment of shares of common stock pursuant to a Section 3(a)(10) exemption from the Securities Act of 1933's registration requirements. As of April 30, 2022, there was a balance outstanding of $176,485 on this judgment that could be converted into approximately 278,690,243 shares of the Company’s common stock at a rate of approximately $0.00063 per share. On November 25, 2014, a judgment in the amount of $2,934,889 was awarded against the Company’s wholly-owned subsidiary, Alaric Corporation. On April 29, 2016, a total of $2,822,209 of this was relinquished pursuant to an exchange of properties. The remaining $112,680 judgment was replaced on May 4, 2016, pursuant to a new judgment. As of April 30, 2022, there was a balance outstanding of $30,449 on this judgment that could be converted into approximately 86,998,604 shares of the Company’s common stock at a rate of approximately $0.00035 per share. As of April 30, 2022 and 2021, the aggregate market value of the Company’s judgments payable in common stock was $6,582,399 and $16,876,585, respectively, based on the closing stock prices of $0.018 and $0.039 per share, respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Apr. 30, 2022
Subsequent Events
Subsequent Events	Note 10 – Subsequent Events The Company evaluates events that have occurred after the balance sheet date through the date hereof, which these financial statements were issued. No events occurred of a material nature that would have required adjustments to or disclosure in these financial statements except as follows: Warrant Exercise On June 1, 2022, a warrant holder exercised warrants to purchase 10,000,000 shares of common stock. The warrants were exercised on a cashless basis, resulting in the issuance of 4,252,874 shares of common stock. Warrant Issuance On August 2, 2022, the Company awarded warrants to a consultant to purchase 250,000 shares of common stock at an exercise price of $0.0128 per share, execrable over a ten-year period. Capital Contributions On May 5, 2022, the Company received $50,000 in contributed capital from Epidemiologic Solutions Corp. Cancellation of Common Stock On July 22, 2022, the Company cancelled 2,028,370 previously issued shares due to non-performance.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Apr. 30, 2022
Significant Accounting Policies (Policies)
Nature of Business	Halberd Corporation (“Halberd”, “We”, “Us”, “the Company”) was formed in the State of Nevada on January 26, 2009. It changed its name to Tykhe Corporation on April 22, 2014, and then redomiciled to Colorado and changed its name to Alaric Corporation on January 25, 2017. On March 22, 2020, it changed its name to HALB Transition Corporation, before completing a reorganization whereby the name of the public company again became Halberd Corporation, and Alaric Corporation then became its wholly-owned subsidiary. The merger was accounted for as a reverse purchase acquisition in accordance with the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) 805-50, whereby the financial statements of the Target company (Halberd Corporation) were treated as the acquiring company, and the equity section of the balance sheet and earnings per share of Halberd Corporation were retroactively restated to reflect the effect of the 1:1 exchange ratio of the equity of Alaric Corporation exchanged for the equity of Halberd Corporation. There were no assets or liabilities of either entity prior to the business combination, therefore there was no Goodwill or gain or loss on the business combination. Halberd’s primary business is the pursuit of treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.
Basis of Accounting	Our financial statements are prepared using the accrual method of accounting as generally accepted in the United States of America (U.S. GAAP) and the rules of the Securities and Exchange Commission (SEC).
Basis of Presentation	The accompanying financial statements include the accounts of the following entities, all of which are under common control and ownership as of the date of this report: Name of Entity Form of Entity State of Incorporation Relationship Halberd Corporation Corporation Colorado Parent Alaric Corporation Corporation Colorado Subsidiary All significant inter-company transactions have been eliminated in the preparation of these financial statements. These statements reflect all adjustments, which in the opinion of management, are necessary for fair presentation of the information contained therein. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. It is suggested that these unaudited financial statements be read in conjunction with the financial statements of the Company for the year ended July 31, 2021 and notes thereto included in the Company's annual report. The Company has adopted a fiscal year end of July 31 st
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Segment Reporting	FASB ASC 280-10-50 requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. All of the Company’s stores are considered operating segments, and will be aggregated into one reportable segment given the similarities in economic characteristics among the operations represented by the stores and the common nature of the products, customers and methods of distribution.
Fair Value of Financial Instruments	Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts payable and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company had a convertible note payable that required fair value measurement on a recurring basis.
Revenue Recognition	The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under Topic 606, revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We determine revenue recognition through the following steps: ● identification of the contract, or contracts, with a customer; ● identification of the performance obligations in the contract; ● determination of the transaction price; ● allocation of the transaction price to the performance obligations in the contract; and ● recognition of revenue when, or as, we satisfy a performance obligation. The Company’s revenues currently consist of the sale of CBD products, including patches, roll-on applications, sprays and ointments. These products are primarily sold direct-to-consumers online, and occasionally directly to local pharmacies. Sales are recorded when the earnings process is complete or substantially complete, and the revenue is measurable and collectability is reasonably assured, which is typically when products are shipped. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue from sales in which payment has been received, but the earnings process has not been completed.
Cost of Merchandise Sales and Occupancy Costs	Cost of merchandise sales and occupancy costs includes the following types of expenses: purchase price of inventory sold, including inbound freight charges; shipping and handling costs; inventory shrinkage costs and valuation adjustments; payroll and benefits costs; store occupancy costs, including rent, common area maintenance, property taxes, utilities, insurance, and depreciation of leasehold improvements and capitalized lease assets. Also included in cost of merchandise sales and occupancy costs is certain consideration received from vendors for vendor rebates, allowances and discounts.
Advertising and Promotion	All costs associated with advertising and promoting products are expensed as incurred. These expenses approximated $53,936 and $46,624 for the nine months ended April 30, 2022 and 2021, respectively, as presented in general and administrative expenses within the consolidated statements of operations.
Research and Development	The Company performs research and development on its extracorporeal technological method of treating many disease states, including Alzheimer’s Disease, PTSD, Parkinson’s Disease, epilepsy and other neurodegenerative diseases, sepsis, meningitis and pandemics. The Company currently does not have any employees dedicated to research and development, but outsources these activities to Arizona State University (ASU) pursuant to an Industry Sponsored Research Agreement, which the Company and ASU entered into on September 1, 2020 (Research Agreement). The Research Agreement, which terminates on November 30, 2022, calls for monthly payments of $50,000, not to exceed $1,371,782, The Company’s research and development activities have primarily been funded by Epidemiologic Solutions Corp.). In accordance with ASC 730-10-25, these expenditures contracted to another party are expensed as incurred. These expenses approximated $710,788 and $471,446 for the nine months ended April 30, 2022 and 2021, respectively.
Income Taxes	The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not.
Basic and Diluted Loss per Share	The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure.
Stock-Based Compensation	The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty's performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Uncertain Tax Positions	In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.
Adoption of New Accounting Standards and Recently Issued Accounting Pronouncements	There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Table)	9 Months Ended
	Apr. 30, 2022
Fair Value of Financial Instruments
Schedule of valuation of financial instruments at fair value on a recurring basis	Fair Value Measurements at April 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 8,162 $ - $ - Total assets 8,162 - - Liabilities Convertible judgments payable - 6,582,399 - Note payable, SBA loan - 150,000 - Total liabilities - 6,732,399 - $ 8,162 $ (6,732,399 ) $ - Fair Value Measurements at July 31, 2021 Level 1 Level 2 Level 3 Assets Cash $ 40,321 $ - $ - Total assets 40,321 - - Liabilities Convertible judgments payable - 15,591,498 - Note payable, SBA loan - 150,000 - Total liabilities - 15,741,498 - $ 40,321 $ (15,741,498 ) $ -

Note Payable, SBA Loan (Table)

Note Payable, SBA Loan (Table)	9 Months Ended
	Apr. 30, 2022
Note Payable, SBA Loan
Note Payable, SBA Loan	April 30, July 31, 2022 2021 On September 2, 2020, the Company, borrowed $150,000 from Standard Financing, pursuant to a Promissory Note issued by the Company to Standard Financing (the “SBA Loan”). The loan was made pursuant to the Covid-19 Economic Injury Disaster Loan Program established as part of the Coronavirus Aid, Relief, and Economic Security Act (the “EIDL Program”). The SBA Loan carried interest at 3.75% per annum, payable in $731 monthly payments over thirty (30) years from the date of the note, with the initial payment deferred until September 2, 2022. $ 150,000 $ 150,000 Total note payable, SBA loan $ 150,000 $ 150,000

Income Taxes (Table)

Income Taxes (Table)	9 Months Ended
	Apr. 30, 2022
Subsequent Events
Schedule of deferred tax asset	April 30, July 31, 2022 2021 Deferred tax assets: Net operating loss carry forwards $ 826,350 $ 640,500 Net deferred tax assets before valuation allowance $ 826,350 $ 640,500 Less: Valuation allowance (826,350 ) (640,500 ) Net deferred tax assets $ - $ -
Schedule of statutory income tax rate	April 30, July 31, 2022 2021 Federal and state statutory rate 21 % 21 % Change in valuation allowance on deferred tax assets (21%) (21%)

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021
Significant Accounting Policies (Policies)
Research and development agreement description			The Research Agreement, which terminates on November 30, 2022, calls for monthly payments of $50,000, not to exceed $1,371,782
Research and development	$ 203,408	$ 199,664	$ 710,788	$ 471,446
Advertising and promotion expenses			$ 53,936	$ 46,624

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Significant Accounting Policies (Policies)
Accumulated deficit	$ (6,184,553)	$ (4,820,050)
Working capital	$ (470,892)

Convertible Judgments Payable_2

Convertible Judgments Payable and Contingent Liabilities (Details Narrative) - USD ($)		1 Months Ended	9 Months Ended
	May 07, 2014	Nov. 25, 2014	Apr. 30, 2022	Feb. 18, 2022	Jul. 31, 2021
Shares issued in satisfaction of obligation			486,850,070
Issuance of aggregate common shares			392,732,957
Legal court settlement description			Order, including any obligation to issue the 486,850,070 shares … and …. to receive shares in any of the other Issuers is hereby extinguished. The 19,438,077 shares, which Halberd was obligated to issue SCI shall increase to 321,943,143, to reflect the corresponding decrease in its share price
Outstanding balance amount as per judgement			$ 30,449
Common stock conversion price per share			$ 0.00035
Shares issued in satisfaction of obligation amount				$ 82,231
Balance outstanding converted into common stock shares			86,998,604
Common stock amount divided into shares, price per share			$ 0.00063
Payment for legal settlement, amount	$ 279,447
Accrued liability			$ 9,717		$ 5,300
Balance outstanding on legal settlement			$ 176,485
SCI
Shares issued in satisfaction of obligation			19,438,077
Increase number of shares issued in satisfaction of obligation			321,943,143
Common stock amount divided into shares, amount		$ 112,680
Common stock amount divided into shares, shares		321,943,143
Common stock amount divided into shares, price per share		$ 0.00035
Case No. 13 L 00000668
Shares issued in satisfaction of obligation			162,588,671
Balance outstanding converted into common stock shares			278,690,243
Common stock amount divided into shares, price per share			$ 0.00063
Payment for legal settlement, amount	$ 279,447
Common Stock shares issued for settlement	441,278,914
Balance outstanding on legal settlement			$ 176,485
Case No. 14 L 825
Shares issued in satisfaction of obligation		19,438,077
Payment for legal settlement, amount		$ 2,822,209
Common Stock shares issued for settlement		486,850,070
Common stock, shares issued price per shares		$ 0.0057969
Accrued liability		$ 112,680

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - USD ($)	Apr. 30, 2022	Jul. 31, 2021	Apr. 30, 2021	Jul. 31, 2020
Assets
Cash	$ 8,162	$ 40,321	$ 108,003	$ 2,086
Total assets	18,391	63,352
Note payable, SBA loan	150,000	150,000
Total liabilities	634,464	548,710
Level 2
Assets
Cash	0	0
Total assets	0	0
Convertible judgments payable	6,582,399	15,591,498
Note payable, SBA loan	150,000	150,000
Total liabilities	6,732,399	15,741,498
Fair value assets and liabilities	(6,732,399)	(15,741,498)
Level 3
Assets
Cash	0	0
Total assets	0	0
Convertible judgments payable	0	0
Note payable, SBA loan	0	0
Total liabilities	0	0
Fair value assets and liabilities	0	0
Level 1
Assets
Cash	8,162	40,321
Total assets	8,162	40,321
Convertible judgments payable	0	0
Note payable, SBA loan	0	0
Total liabilities	0	0
Fair value assets and liabilities	$ 8,162	$ 40,321

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Details 1) - Level 2 - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Convertible judgments payable	$ 6,582,399	$ 15,591,498
Historical value of convertible judgments payable on balance sheets	206,935	216,400
Total	$ 6,375,464	$ 15,375,098

Note Payable, SBA Loan (Details

Note Payable, SBA Loan (Details) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Total note payable, SBA loan	$ 150,000	$ 150,000
Coronavirus Aid, Relief, and Economic Security Act
Total note payable, SBA loan	$ 150,000	$ 150,000

Note Payable, SBA Loan (Detai_2

Note Payable, SBA Loan (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2022	Apr. 30, 2021
Note Payable, SBA Loan
Interest expense on notes payable	$ 4,417	$ 3,839

Changes in Stockholders' Equi_2

Changes in Stockholders' Equity (Deficit) (Details Narrative) - USD ($)	1 Months Ended			3 Months Ended		9 Months Ended
	Apr. 27, 2022	Feb. 21, 2022	Feb. 18, 2022	Apr. 30, 2022	Apr. 30, 2021	Apr. 30, 2022	Apr. 30, 2021	Jul. 31, 2021
Common Stock Issued in Satisfaction of Judgments Payable, shares			27,044,110
Common Stock Issued in Satisfaction of Judgments Payable, amount			$ 9,466
Common Stock Issued in Satisfaction of Judgments Payable, per share			$ 0.00035
Common stock, shares cancelled		25,015,740
Contributed capital combined amount	$ 745,000			$ 267,500	$ 217,500	$ 745,000	$ 482,315
Common stock, shares par value				$ 0.0001		$ 0.0001		$ 0.0001
Common stock, shares authorized				800,000,000		800,000,000		800,000,000
Common stock, shares issued				513,650,338		513,650,338		511,621,968
Common stock, shares outstanding				513,650,338		513,650,338		511,621,968
Preferred stock, shares par value				$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares authorized				25,000,000		25,000,000		25,000,000
Preferred stock, shares issued				10,000,000		10,000,000		10,000,000
10000000				10,000,000		10,000,000		10,000,000
Series A Preferred Stock [Member]
Preferred stock, shares par value				$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares authorized				25,000,000		25,000,000		25,000,000
Preferred stock, shares issued				10,000,000		10,000,000		10,000,000
10000000				10,000,000		10,000,000		10,000,000
Preferred stock, designated				10,000,000		10,000,000
Preferred stock, designated remaining shares				15,000,000		15,000,000

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - USD ($)				1 Months Ended
	Jan. 15, 2022	Dec. 15, 2021	Dec. 05, 2021	Apr. 24, 2022	Jan. 22, 2022	Apr. 30, 2022
Warrants to purchase common stock shares						485,850,000
Weighted average strike price						$ 0.01
Amended Warrants [Member]
Warrants to purchase common stock shares			250,000
Warrants exercisable price per share			$ 0.0188
Warrants term			ten-year
Weighted average volatility rate			300%
Weighted average call option, price per share			$ 0.0188
Weighted average call option value			$ 4,696
Warrants to purchase common stock shares, cancelled			250,000
Warrants to purchase common stock shares cancelled, exercisable price per share			$ 0.0235
Warrants Granted for Services [Member]
Warrants to purchase common stock shares	10,000,000	1,000,000	10,000,000	1,000,000	750,000
Warrants exercisable price per share	$ 0.0206	$ 0.0175	$ 0.0188	$ 0.019	$ 0.0196
Warrants term	ten-year	ten-year	ten-year	ten-year	ten-year
Weighted average volatility rate	293%	297%	300%	239%	292%
Weighted average call option, price per share	$ 0.0206	$ 0.0175	$ 0.0188	$ 0.0188	$ 0.0196
Weighted average call option value	$ 205,788	$ 17,484	$ 187,853	$ 18,768	$ 14,685
Warrants Granted for Services one [Member]
Warrants to purchase common stock shares			1,000,000	500,000
Warrants exercisable price per share			$ 0.0188	$ 0.019
Warrants term			ten-year	ten-year
Weighted average volatility rate			300%	239%
Weighted average call option, price per share			$ 0.0188	$ 0.0188
Weighted average call option value			$ 18,785	$ 9,384
Warrants Granted for Services Two [Member]
Warrants to purchase common stock shares			350,000
Warrants exercisable price per share			$ 0.0188
Warrants term			ten-year
Weighted average volatility rate			300%
Weighted average call option, price per share			$ 0.0188
Weighted average call option value			$ 6,575

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Apr. 30, 2022	Jul. 31, 2021
Deferred tax assets:
Net operating loss carry forwards	$ 826,350	$ 640,500
Net deferred tax assets before valuation allowance	826,350	640,500
Less: Valuation allowance	(826,350)	(640,500)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1)	9 Months Ended	12 Months Ended
	Apr. 30, 2022	Jul. 31, 2021
Income Taxes
Federal and state statutory rate	21%	21%
Change in valuation allowance on deferred tax assets	(21.00%)	(21.00%)

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	Apr. 30, 2022 USD ($)
Income Taxes
Federal net operating loss carry forwards	$ 3,935,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)			1 Months Ended		9 Months Ended
	May 04, 2016	May 07, 2014	Apr. 29, 2016	Nov. 25, 2014	Apr. 30, 2022	Jul. 31, 2021	Apr. 30, 2021	Sep. 02, 2020
Outstanding balance amount as per judgement					$ 30,449
Common stock conversion price per share					$ 0.00035
Aggregate market value of judgments payable in common stock					$ 6,582,399		$ 16,876,585
Closing stock price per share					$ 0.018		$ 0.039
Description of research and development agreement commitment					The Company has received a binding funding commitment from Epidemiological Solutions Corporation, a charitable organization recently approved by the Internal Revenue Service and qualified under Internal Revenue Code section 501(c)(3), for $2,000,000 to fund the Company’s research and development endeavors. As of April 30, 2022, $889,782 had been paid on this commitment, beginning with the first payment of $21,782 on, or about, September 2, 2020, as presented as Contributed Capital within the Statement of Stockholders Equity (Deficit). The charitable organization is committed to monthly payments of $50,000 pursuant to its sponsored research agreement with Arizona State University.
Government assistance amount	$ 112,680		$ 2,822,209	$ 2,934,889
Balance outstanding amount converted into common stock shares					$ 278,690,243
Research agreement description					The Research Agreement, which terminates on November 30, 2022, calls for monthly payments of $50,000, not to exceed $1,371,782.
Aggregate payment paid by company						$ 521,782
Agreement leaving amount						$ 850,000
Balance outstanding converted into common stock shares					86,998,604
Payment for legal settlement, amount		$ 279,447
Balance outstanding on legal settlement					$ 176,485
Common stock, conversion price per shares					$ 0.00063
Epidemiological Solutions Corporation
Contributed Capital amount paid					$ 889,782
Contributed capital amount, first payment								$ 21,782
Monthly payments pursuant to sponsored research agreement							$ 50,000
Maximum monthly payments pursuant to sponsored research agreement					$ 1,371,782
Research Agreement, terminate date					Nov. 30, 2022
Monthly payment					$ 50,000
Fund for research and development endeavors					$ 2,000,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)		1 Months Ended
	Aug. 02, 2022	Jul. 22, 2022	Jun. 01, 2022	May 05, 2022
Exercised warrants to purchase shares of common stock			10,000,000
Issuance of of common stock shares			4,252,874
Captial contribution				$ 50,000
Shares cancelled		2,028,370
Consultant [Member]
Exercised warrants to purchase shares of common stock	250,000
Warrants exercise price	$ 0.0128
Warrants execrable period	10 years